Triste, Sherlyn B.
HRN: 04-46-44 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/21/2025
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
06/21/2025
07/04/2025
IV
1.5g
Q8
Infected Breast Mass
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes